Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 study of erlotinib in pancreatic cancer that can be removed by surgery was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraductal Papillary Mucinous Neoplasm of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-05-19